Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
AssigneePharmexa Inc.
InventorsAlessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Howard M. Grey
Life of this patent
Estimating the term…
Abstract
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Claims32
An isolated prepared human papilloma virus (HPV) epitope consisting of a sequence selected from the group consisting of the sequences set out in Tables VII-XX.
A clonal cytotoxic T lymphocyte (CTL), wherein the CTL is cultured in vitro and binds to a complex of an epitope selected from the group set out in Tables VII-XVIII, bound to an HLA molecule.
A peptide comprising at least a first and a second epitope, wherein the first epitope is selected from the group consisting of the sequences set out in Tables VII-XX;
- wherein the peptide comprise less than 50 contiguous amino acids that have 100% identity with a native peptide sequence.
A vaccine composition comprising:
- a unit dose of a peptide that comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence of HPV, the peptide comprising at least a first epitope selected from the group consisting of the sequences set out in Tables VII-XX;
- and;
- a pharmaceutical excipient.
An isolated nucleic acid encoding a peptide comprising an epitope consisting of a sequence selected from the group consisting of the sequences set out in Tables VII-XX.
An isolated nucleic acid encoding a peptide comprising at least a first and a second epitope, wherein the first epitope is selected from the group consisting of the sequences set out in Tables VII-XX;
- and wherein the peptide comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence.
Dependencies are inferred from the claim text.